Antipsychotic therapy: A pharmacoeconomic perspective

American Journal of Health-System Pharmacy

Volumn 59, Issue SUPPL. 8, 2002, Pages

  Rey, José A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Antipsychotic agents; Costs; Dosage; Pharmacoeconomics; Schizophrenia; Toxicity

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

COMORBIDITY; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; LONG TERM CARE; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RESOURCE MANAGEMENT; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0037111590     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.suppl_8.s5     Document Type: Conference Paper

References (12)

1. Murray CJL, Lopez AD, eds. Global Burden of Disease. Cambridge, MA: Harvard Univ. Press; 1996.
2. Pardes H. The report of the National Advisory Mental Health Council. Am J Psychiatry. 1993; 50:1445-6.
3. Wyatt RJ, Henter I, Leary MC et al. An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol. 1995; 30:196-205.
4. Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry. 1995; 40(7, suppl 2):S60-7.
5. Talbott JA, Goldman HH, Ross L. Schizophrenia: An economic perspective. Psychiatr Ann. 1987; 17:577-9.
6. Drummond MF, O'Brien B, Stoddard GL et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd Ed. Oxford, England: Oxford Univ. Press; 1997.
7. Byerly M, Thompson A, Brooks D et al. Cost-outcomes of risperidone vs. olanzapine: A computer database and chart review comparison at five Veterans Administration sites. Paper presented at the American Psychiatric Association Institute on Psychiatric Services Meeting. Orlando, FL; 2001 Oct 10-14.
8. Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Guideline for Atypical Antipsychotic Use. Washington, DC: Department of Veterans Affairs, 2002; publication PBM-SHG.
9. Rey JA, Nova Southeastern University. Unpublished data. 2002 Jul.
10. Earlywine K, Rey JA. Outcomes analysis of risperidone and clozapine vs. conventional antipsychotics. Paper presented at 28th Annual Southeastern Residency Conference. Athens, GA; 1997 Apr.
11. Leslie DL, Rosencheck R. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia. J Nerv Ment Dis. 2001; 189:377-83.
12. Delgado L, Rey JA, McKoy Y et al. A comparison of clinical outcomes in patients receiving depot vs. atypical antipsychotics. Paper presented at 40th Annual NCDEU-NIMH Meeting. Boca Raton, FL; 2000 Jun.